The 0.16x price/sales and 0.65x price/book multiples — the latter essentially at Shoe Carnival's 0.62x and Caleres' 0.66x — indicate the market assigns Genesco no meaningful franchise premium despite its ~47% gross margins; the gap appears to sit almost entirely in the earnings denominator, where a 2027Q2 net margin of 0.7% leaves little to capitalize. The 4.6x P/FCF is the most flattering reading and may reflect the working-capital inflows Genesco harvested rather than durable operating generation, so investors should discount it as a recurring signal. Even at 10.2x EV/EBITDA, roughly in line with Boot Barn's 11.4x, the multiple embeds an implicit assumption that EBITDA recovers toward holiday-quarter levels, which warrants monitoring given that ROIC remains near zero.

The decomposition points to SG&A, not product economics, as the binding constraint: with SG&A near $259.6M — approximately 49% of revenue — and no R&D offset, a 3.0% year-over-year revenue decline is enough to push the operating line negative, which suggests operating leverage is currently working in reverse. The 2026Q4 quarter, with a 6.8% operating margin on peak revenue, appears to be the only period where the fixed cost base was sufficiently absorbed, implying true earning power is closer to a mid-single-digit EBITDA margin than to the reported net margin swings between -5.3% and +6.0%. Non-cash items further muddy the net line, so operating margin or EBITDA margin is the more reliable lens on earning power here.

The combination of a 21% expansion in net property and equipment to $766.1M, a softening asset turnover of 0.37, and ROIC averaging near zero suggests Genesco is not compounding returns on the capital it has deployed, which is the key judgment separating a cyclical trough from structural decay. ROE at 0.6% compares with 18.8% at Boot Barn and 3.6% at Shoe Carnival, and because the equity base has held roughly flat while retained earnings were drawn down, the gap is a margin-and-efficiency problem rather than a leverage-driven one. If returns persist below the cost of capital through the next holiday cycle, the equity premium embedded in the 2.84x book multiple commanded by the stronger peer would be difficult to justify.

A 165-day DIO — far longer than the 8-day DSO typical of a card-funded retailer — indicates the business funds itself from customers essentially instantly but locks capital in merchandise for over five months, which is why the quick ratio of 0.32 sits so far below the 1.58 current ratio. DPO near 56 days, essentially stable across the ten-quarter window, suggests supplier terms are neither being extended to fund the inventory build nor tightened, implying Genesco holds conventional rather than unusual trade leverage. The 46-day seasonal compression in the CCC between Q2 and Q4 appears to be a genuine earnings-season cash harvest, but it also means the balance sheet's headline liquidity is largely a function of where in the seasonal cycle a snapshot falls.

Leverage has effectively plateaued rather than declined: D/E held above 0.9 in all ten quarters while equity stayed near $557M, so the debt-funded asset build has not translated into retained-earnings accretion that would reduce the ratio organically. The more informative measure is D/EBITDA, which printed 7.7x in the strong 2026Q4 quarter but jumped to 23.4x in the lean 2026Q3 quarter, meaning the leverage picture looks materially different depending on which earnings period is annualized — a judgment that should be anchored on the peak quarter for durability. On current figures there is no visible refinancing cliff in the data provided, but coverage of negative quarters cannot be assessed and investors should treat the positive coverage readings as peak-cycle rather than through-cycle evidence.